Overview
STERIS plc is a healthcare company headquartered in Ireland, chiefly engaged in the manufacturing and sale of infection prevention, decontamination, and surgical and critical care products. The company primarily serves hospitals, pharmaceutical firms, and medical device manufacturers. A major component of STER minvolves innovative sterilization and disinfection technologies, including both consumables and equipment. Their portfolio spans a broad range of products such as sterilizers, washers, surgical tables, and connectivity solutions like OR integration systems. STERIS is also actively involved in developing environmentally friendly products and technologies, aligning its projects with global sustainability trends. This strategic focus aims to leverage technological advances to elevate both the efficacy and efficiency of critical healthcare processes around the world.
AI+ Ask Fintel’s AI assistant about STERIS plc.
Thinking about good questions…
Basic Stats
The share price of STERIS plc as of September 5, 2025 is $245.30 / share. This is an increase of 0.10% from the prior week. The market cap (or net worth) of STERIS plc as of September 5, 2025 is $24,130.40 MM.
The Factor Analysis chart (below right) shows a view of STERIS plc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 24,130.40 MM |
| EV | 25,894.65 MM |
| Shares Out. | 98.37 MM |
| Earnings Date | |
| EPS (TTM) | 6.57 |
| Dividend Yield | 0.93 % |
| Ex-Dividend Date | 2025-09-04 |
| Borrow Rate | 1.23 |
| Short Shares Avail. | 1.60 MM |
| Short Interest | 0.91 MM |
| Short Float | 0.92 % |
| Days to Cover | 2.88 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 2.63 % |
| Volatility (1 yr) | 0.23 |
| Beta | 0.47 |
| Sharpe Ratio (1 yr) | -0.07 |
| Sortino Ratio (1 yr) | -0.13 |
| PE Ratio | 37.32 |
| Price/Book | 3.46 |
| Price/TBV | 25.96 |
| Book/Market | 0.29 |
| EBIT/EV | 0.03 |
| EBIT(3yr avg)/EV | 0.02 |
| ROA | 0.06 |
| ROE | 0.10 |
| ROIC | 0.07 |
| CROIC | 0.01 |
| OCROIC | 0.14 |
| Implied Volatility | 17.08 % |
| Put/Call OI Ratio | 1.09 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for STERIS plc is $277.94. The forecasts range from a low of $234.22 to a high of $309.75. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for STERIS plc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2021-02-04 | KeyBanc | Sector Weight | Overweight | Upgrade |
| 2020-09-02 | Baird | Outperform | Initiate | |
| 2020-06-09 | Needham | Hold | Initiate | |
| 2020-03-23 | Stephens & Co. | Overweight | Maintains | |
| 2020-02-12 | Stephens & Co. | Overweight | Maintains | |
| 2019-07-10 | KeyBanc | Overweight | Sector Weight | Downgrade |
| 2019-05-22 | JMP Securities | Market Outperform | Maintains | |
| 2019-05-15 | KeyBanc | Overweight | Maintains | |
| 2018-12-06 | Sidoti & Co. | Buy | Buy | Maintains |
| 2018-11-13 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-08-09 | KeyBanc | Overweight | Overweight | Maintains |
| 2018-08-09 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2018-01-03 | Raymond James | Outperform | Market Perform | Downgrade |
| 2017-11-02 | KeyBanc | Overweight | Maintains | |
| 2017-10-16 | Raymond James | Outperform | Maintains | |
| 2017-08-09 | Raymond James | Outperform | Maintains | |
| 2017-05-03 | KeyBanc | Sector Weight | Overweight | Upgrade |
| 2016-11-30 | Goldman Sachs | Neutral | Initiate | |
| 2015-06-12 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2015-06-04 | KeyBanc | Downgrade | ||
| 2015-02-05 | JMP Securities | Market Outperform | Maintains | |
| 2014-10-22 | Raymond James | Market Perform | Strong Buy | Upgrade |
| 2014-04-02 | Stephens & Co. | Equal-Weight | Overweight | Upgrade |
| 2013-05-07 | Griffin Securities | Buy | Hold | Downgrade |
| 2013-03-15 | Bank of America | Buy | Maintains | |
| 2012-12-21 | Raymond James | Market Perform | Initiate | |
| 2012-09-20 | Bank of America | Buy | Initiate | |
| 2012-08-03 | JMP Securities | Market Perform | Outperform | Upgrade |
| 2022-11-11 | Keybanc | Overweight | Maintains | |
| 2022-09-23 | Needham | Buy | Hold | Downgrade |
| 2022-08-04 | Needham | Buy | Maintains | |
| 2022-08-04 | Keybanc | Overweight | Maintains | |
| 2022-07-14 | Piper Sandler | Overweight | Initiate | |
| 2022-05-13 | Needham | Buy | Maintains | |
| 2022-02-14 | JMP Securities | Market Outperform | Maintains | |
| 2022-02-10 | Needham | Buy | Maintains | |
| 2021-11-04 | Stephens & Co. | Overweight | Maintains | |
| 2021-11-04 | Keybanc | Overweight | Maintains | |
| 2021-08-11 | Stephens & Co. | Overweight | Maintains | |
| 2021-08-11 | Keybanc | Overweight | Maintains | |
| 2021-08-11 | Baird | Outperform | Maintains | |
| 2021-05-26 | Needham | Hold | Buy | Upgrade |
| 2021-05-11 | JMP Securities | Market Outperform | Maintains | |
| 2021-03-11 | KeyBanc | Overweight | Maintains | |
| 2023-02-10 | Piper Sandler | Overweight | Maintains | |
| 2023-02-09 | Stephens & Co. | Overweight | Maintains | |
| 2023-02-15 | JMP Securities | Market Outperform | Maintains | |
| 2023-04-14 | Piper Sandler | Overweight | Neutral | Downgrade |
| 2023-05-11 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-05-12 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-05-12 | Keybanc | Overweight | Overweight | Maintains |
| 2023-05-30 | Morgan Stanley | Equal-Weight | Initiate | |
| 2023-10-26 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-12-04 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-09-01 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2023-09-25 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2023-08-03 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2023-08-03 | Keybanc | Overweight | Overweight | Maintains |
| 2023-07-17 | Stephens & Co. | Overweight | Overweight | Maintains |
| 2023-10-27 | Piper Sandler | Neutral | Neutral | Maintains |
| 2023-08-02 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-07-25 | Keybanc | Overweight | Overweight | Maintains |
| 2023-11-09 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-02-06 | Keybanc | Overweight | Initiate | |
| 2024-05-09 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-02-09 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-04-12 | Needham | Hold | Reiterate | |
| 2024-05-10 | Piper Sandler | Neutral | Neutral | Reiterate |
| 2024-02-08 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-05-10 | Needham | Hold | Reiterate | |
| 2024-07-26 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-11-08 | Needham | Hold | Reiterate | |
| 2024-09-03 | Keybanc | Overweight | Overweight | Maintains |
| 2025-05-16 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-08-07 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-08-08 | Needham | Hold | Reiterate | |
| 2024-08-07 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-04-07 | Needham | Hold | Hold | Reiterate |
| 2024-11-07 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-05-29 | Jefferies | Hold | Initiate | |
| 2024-11-18 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-10-24 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2025-02-03 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-02-06 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-02-06 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-05-15 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-05-19 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-10 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-07-22 | Keybanc | Overweight | Overweight | Maintains |
| 2025-07-15 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
